210 related articles for article (PubMed ID: 8722054)
1. Fibrinolysis and diabetic retinopathy in NIDDM.
Mansfield MW; Grant PJ
Diabetes Care; 1995 Dec; 18(12):1577-81. PubMed ID: 8722054
[TBL] [Abstract][Full Text] [Related]
2. Plasma t-PA and PAI-1 antigen concentrations in non-insulin dependent diabetic patients: implication for diabetic retinopathy.
Cho YW; Yang DH; Oh DY; Baick SH; Kim SK; Kim SJ; Hong SY
Diabetes Res Clin Pract; 1994 Jan; 22(2-3):123-8. PubMed ID: 8200293
[TBL] [Abstract][Full Text] [Related]
3. Plasminogen activator inhibitor (PAI-1) activity is elevated in Asian and Caucasian subjects with non-insulin-dependent (type 2) diabetes but not in those with impaired glucose tolerance (IGT) or non-diabetic Asians.
Nagi DK; Mohamed Ali V; Jain SK; Walji S; Yudkin JS
Diabet Med; 1996 Jan; 13(1):59-64. PubMed ID: 8741814
[TBL] [Abstract][Full Text] [Related]
4. Changes in fibrinolytic parameters in male patients with type 2 (non-insulin-dependent) diabetes mellitus.
Takada Y; Urano T; Watanabe I; Taminato A; Yoshimi T; Takada A
Thromb Res; 1993 Sep; 71(5):405-15. PubMed ID: 8236167
[TBL] [Abstract][Full Text] [Related]
5. [Tissue-type plasminogen activator and its inhibitor (PAI-1) in plasma in cases of non-insulin-dependent diabetes mellitus (NIDDM)].
Jokaji H; Asakura H; Saito M; Uotani C; Kumabashiri I; Morishita E; Yamazaki M; Matsuda T
Nihon Ronen Igakkai Zasshi; 1990 Nov; 27(6):699-705. PubMed ID: 2127812
[TBL] [Abstract][Full Text] [Related]
6. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects.
Kruszynska YT; Yu JG; Olefsky JM; Sobel BE
Diabetes; 2000 Apr; 49(4):633-9. PubMed ID: 10871202
[TBL] [Abstract][Full Text] [Related]
7. The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes.
Grant PJ
Diabetes Care; 1996 Jan; 19(1):64-6. PubMed ID: 8720537
[TBL] [Abstract][Full Text] [Related]
8. Circulating tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in proliferative diabetic retinopathy: a pilot study.
Simpson AJ; Booth NA; Moore NR; Lewis SJ; Gray RS
Acta Diabetol; 1999 Sep; 36(3):155-8. PubMed ID: 10664320
[TBL] [Abstract][Full Text] [Related]
9. The effect of obesity on fibrinolytic activity and plasma lipoprotein (a) levels in patients with type 2 diabetes mellitus in Korea.
Park YS; Park S; Park KS; Kim SY; Lee HK; Koh CS; Min HK; Kim JQ
Diabetes Res Clin Pract; 1994 May; 24(1):25-31. PubMed ID: 7924883
[TBL] [Abstract][Full Text] [Related]
10. Association of plasminogen activator inhibitor-1 and tissue plasminogen activator with type 2 diabetes and metabolic syndrome in Malaysian subjects.
Al-Hamodi Z; Ismail IS; Saif-Ali R; Ahmed KA; Muniandy S
Cardiovasc Diabetol; 2011 Mar; 10():23. PubMed ID: 21414238
[TBL] [Abstract][Full Text] [Related]
11. Short-term oestrogen replacement therapy improves insulin resistance, lipids and fibrinolysis in postmenopausal women with NIDDM.
Brussaard HE; Gevers Leuven JA; Frölich M; Kluft C; Krans HM
Diabetologia; 1997 Jul; 40(7):843-9. PubMed ID: 9243107
[TBL] [Abstract][Full Text] [Related]
12. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients.
McGill JB; Schneider DJ; Arfken CL; Lucore CL; Sobel BE
Diabetes; 1994 Jan; 43(1):104-9. PubMed ID: 8262307
[TBL] [Abstract][Full Text] [Related]
13. Impaired fibrinolytic compensation for hypercoagulability in obese patients with type 2 diabetes: association with increased plasminogen activator inhibitor-1.
Aso Y; Matsumoto S; Fujiwara Y; Tayama K; Inukai T; Takemura Y
Metabolism; 2002 Apr; 51(4):471-6. PubMed ID: 11912556
[TBL] [Abstract][Full Text] [Related]
14. No influence of proinsulin and insulin on plasma levels of plasminogen activator inhibitor type 1 and tissue plasminogen activator in young women before and during intake of contraceptive steroids.
Petersen KR; Kjems LL; Skouby SO; Andersen LF; Jespersen J
Metabolism; 1996 Jul; 45(7):833-7. PubMed ID: 8692017
[TBL] [Abstract][Full Text] [Related]
15. Sex differences in coagulation and fibrinolysis in white subjects with non-insulin-dependent diabetes mellitus.
Mansfield MW; Heywood DM; Grant PJ
Arterioscler Thromb Vasc Biol; 1996 Jan; 16(1):160-4. PubMed ID: 8548417
[TBL] [Abstract][Full Text] [Related]
16. Improvement by the insulin-sensitizing agent, troglitazone, of abnormal fibrinolysis in type 2 diabetes mellitus.
Kato K; Yamada D; Midorikawa S; Sato W; Watanabe T
Metabolism; 2000 May; 49(5):662-5. PubMed ID: 10831180
[TBL] [Abstract][Full Text] [Related]
17. The role of strict metabolic control by insulin infusion on fibrinolytic profile during an acute coronary event in diabetic patients.
Melidonis A; Stefanidis A; Tournis S; Manoussakis S; Handanis S; Zairis M; Dadiotis L; Foussas S
Clin Cardiol; 2000 Mar; 23(3):160-4. PubMed ID: 10761802
[TBL] [Abstract][Full Text] [Related]
18. Increased plasminogen activator inhibitor-1 activity in offspring of type 2 diabetic patients: lack of association with plasma insulin levels.
Gürlek A; Bayraktar M; Kirazli S
Diabetes Care; 2000 Jan; 23(1):88-92. PubMed ID: 10857975
[TBL] [Abstract][Full Text] [Related]
19. Tissue plasminogen activator and plasminogen activator inhibitor-1 in stroke patients.
Lindgren A; Lindoff C; Norrving B; Astedt B; Johansson BB
Stroke; 1996 Jun; 27(6):1066-71. PubMed ID: 8650716
[TBL] [Abstract][Full Text] [Related]
20. Fibrinolytic response to venous occlusion in healthy subjects: relationship to age, gender, body weight, blood lipids and insulin.
Stegnar M; Pentek M
Thromb Res; 1993 Jan; 69(1):81-92. PubMed ID: 8465277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
